Melinda L. Munang

Melinda L. Munang

Auto-generated profile, based on publicly available information

Melinda L. Munang

Department of Infection and Tropical Medicine, Birmingham Heartlands Hospital, Birmingham B9 5SS, UK School of Life Sciences, University of Warwick, Coventry CV4 7AL, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in QJM: An International Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MMM. L. Munang
M. L. Munang
MKM. Kariuki
M. Kariuki
MDM. Dedicoat
M. Dedicoat
Background : There have been few studies on risk factors and treatment outcomes of isoniazid (H)-resistant tuberculosis (TB), and optimal treatment regimens are debated. Aim : To identify risk factors for H-resistant TB, describe treatment regimens and compare these to national guidelines and describe short-term outcomes of H-resistant TB in Birmingham, UK. Design : Retrospective case series. Methods : Cases of H-resistant tuberculosis in Birmingham between January 1999 and December 2010 ( n = 89) were compared with drug-susceptible cases ( n = 2497). Treatment regimens and outcomes at 12 months from diagnosis were evaluated by case note review. Results : No independent predictors for H-resistant TB were found. For 76/89 (85%) patients with full treatment details available, median treatment duration was 11 months (interquartile range 9–12 months). Only 27/72 (38%) patients with H-monoresistance were treated in line with national guidelines. A further 14/72 (19%) were treated according to other recognized guidelines. Overall treatment success was 75/89 (84%). Treatment failure occurred in 6/89 (7%) patients, all developed multi-drug resistance. Poor adherence was documented in these patients and use of a non-standard regimen in one patient was not thought to have contributed to treatment failure. Conclusions : No discriminating risk factors for early detection of H-resistant TB were found. Treatment regimens in clinical practice were highly varied. H-resistance can drive MDR-TB when there is evidence or suspicion of poor adherence. A low threshold for enhanced case management with directly observed therapy is warranted in this group.

1 March 2015 in Emerging Infectious Diseases
Verified
Journal Article
Open access
MMMelinda L. Munang
Melinda L. Munang
CBCatherine Browne
Catherine Browne
SKShaina Khanom
Shaina Khanom
JEJason T. Evans
Jason T. Evans
ESE. Grace Smith
E. Grace Smith
MDMartin J. Dedicoat
Martin J. Dedicoat
To determine if local transmission was responsible for rising tuberculosis incidence in a recently dispersed migrant community in Birmingham, UK, during 2004–2013, we conducted enhanced epidemiologic investigation of molecular clusters. This technique identified exact locations of social mixing and chains of apparent recent transmission, which can be helpful for directing resources.

16 October 2014 in BMJ
Verified
Journal Article
Closed access
PDF file
MMMelinda L Munang
Melinda L Munang
MOMatthew K O’shea
Matthew K O’shea
MDMartin Dedicoat
Martin Dedicoat
A 56 year old man presented with pain and numbness in his lower legs. He had been treated for pulmonary tuberculosis for the previous six weeks. He thought that his symptoms had started a fortnight previously, after the tuberculosis clinic changed his treatment from a fixed dose combination preparation to multiple, separate drugs. He thought that the new tablets may be causing his symptoms. His partner was also being treated for tuberculosis but with even fewer tablets taken once weekly, and he wondered whether he could take the same treatment as she had. He had a history of excess alcohol intake and admitted to binge drinking at the weekends. Successful tuberculosis treatment requires a prolonged (six months or more) multidrug regimen consisting of agents active against different mycobacterial targets, as populations of bacilli with variable intrinsic resistance exist in several different states of replication and persistence within an infected host. Achieving high treatment completion rates is a key component of tuberculosis control. Globally, of the 6.1 million cases of tuberculosis notified in 2012, 0.4 million were patients who had not completed a previous course of first line treatment.1 These patients have a higher prevalence of multidrug resistant tuberculosis (table 1⇓),1 2 which is more challenging to treat because second line drugs for tuberculosis are less effective and more toxic. Thus, simpler and shorter treatment regimens for drug sensitive tuberculosis and more efficacious and safer regimens for multidrug resistant tuberculosis are needed. View this table: Table 1 Terms and definitions used to denote drug susceptibility and resistance in tuberculosis In this article, we will review fixed dose combinations of the first line antituberculosis drugs; fluoroquinolones as second line drugs with potential for shortening treatment of drug sensitive tuberculosis; and bedaquiline and delamanid, the first new drugs for multidrug resistant tuberculosis with novel …

1 October 2013 in Journal of Clinical Virology
Verified
Journal Article
Closed access
MMMelinda L. Munang
Melinda L. Munang
AMAnupama Mutagi
Anupama Mutagi
MBMark S. Bailey
Mark S. Bailey
HOHusam Osman
Husam Osman